Nov 30, 2021 / 03:05PM GMT
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - Senior MD
Okay. Thanks, everyone, for joining us this morning. I'm Vijay Kumar. I cover Life Science Tools and MedTech at Evercore. Pleasure to have with us at QIAGEN. We have with us Roland Sackers, the CFO. I think I might have John Gilardi as well on. There he is. I could see John waving out there.
It's always -- QIAGEN has been near and dear, it was for a variety of reasons over the years. It's -- unfortunately, we couldn't be part of the story for the last couple of years, but it's certainly been exciting for you guys.
Questions and Answers:
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - Senior MDFrom a far, Roland, when I think about the story, what the debate was 3 years ago versus now, it's changed. So I do want to dive in some of these things. But before I ask on the fundamentals, what's changed, maybe perhaps a lot of questions, can diagnostic companies detect a new Omicron variant? So maybe talk about whether your test
Trustpilot
